ArticleFrontiers in oncology2025
Clinical characteristics of diffuse large B-cell lymphoma complicated with multiple primary malignant neoplasms.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Timing of multiple primary malignancies does not affect overall survival in lymphoma patients: a comparative study of 167 synchronous vs. metachronous cases.American journal of cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the clinical features and prognosis of diffuse large B-cell lymphoma (DLBCL) combined with multiple primary malignant neoplasms (MPMNs). Methods: The clinical data and prognosis of 31 patients with DLBCL combined with MPMNs diagnosed by pathology between January 2012 and April 2024 in the Department of Hematology, Affiliated Hospital of Xuzhou Medical University were retrospectively analyzed. Results: Between January 2012 and April 2024, a total of 937 patients were diagnosed with DLBCL, among whom 31 patients had MPMN, with an incidence rate of 3.3%. The cases were divided into two groups according to the different occurrence intervals of the two tumor types. There were 10 patients in the synchronous MPMN group and 21 in the metachronous MPMN group. Statistically significant differences in gender ( Conclusions: DLBCL combined with MPMNs is rare in the clinic. Age 1≥60 years and shorter time interval between the two tumors are the main factors affecting poor prognosis. Early diagnosis and treatment of DLBCL with MPMNs should be prioritized clinically to prevent misdiagnosis and enhance patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.